$BMY and $PFE facing risk from accelerated Eliquis generic which was supposed to go generic in Nov 2026 but generic manufacturers are suing to invalidate a patent and accelerate this to Feb 2023. Approx. 24% of sales for BMY, 10% for PFE in Q1 2020.